Abstract
Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Anti-Cancer Agents in Medicinal Chemistry
Title: Evolving Therapies and FAK Inhibitors for the Treatment of Cancer
Volume: 10 Issue: 10
Author(s): Kelli Bullard Dunn, Melissa Heffler and Vita M. Golubovskaya
Affiliation:
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Abstract: Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Export Options
About this article
Cite this article as:
Bullard Dunn Kelli, Heffler Melissa and M. Golubovskaya Vita, Evolving Therapies and FAK Inhibitors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728657
DOI https://dx.doi.org/10.2174/187152010794728657 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Insomnia, Insomnia Symptoms, and Obstructive Sleep Apnea During and After Menopause: Therapeutic Approaches
Current Psychiatry Reviews Impact of Opioid Receptor, Mu 1 (OPRM1) Polymorphisms on Pain Sensitivity and Clinical Response to Opioid Analgesic Therapy
Current Pharmacogenomics and Personalized Medicine Modelling DNA Repair Pathways: Recent Advances and Future Directions
Current Pharmaceutical Design Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Dynamics, Density Functional Theory, Pharmacophore Modeling, Molecular Interaction Fields and ADME/Tox Investigation of Novel Bioactive Compounds Interacting with CDK2 Surfaces
Current Physical Chemistry Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Furan-induced Oxidative Stress and DNA Damage in Diabetic and Nondiabetic Rats’ Blood and Protective Effect of Lycopene
Current Nutrition & Food Science Future Approaches for Treating Hematologic Disease
Current Pharmaceutical Biotechnology Cell-based Assays for Assessing Toxicity: A Basic Guide
Medicinal Chemistry Lipid-Coated Nanosized Drug Delivery Systems for an Effective Cancer Therapy
Current Drug Delivery Nanomedicines for Intravesical Chemotherapy in Bladder Cancer
Current Pharmaceutical Design Actual and Potential Agents and Biomarkers in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Current Management of Alcoholic Liver Disease
Current Drug Abuse Reviews Target-based Anti-angiogenic Therapy in Breast Cancer
Current Pharmaceutical Design Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Meet Our Executive Guest Editor
Current Cancer Drug Targets Targeting Mitochondrial Citrate Transport in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine